Senicapoc (ICA-17043) is a Gardos channel blocker.
It has been proposed for use in
sickle cell anemia
Sickle cell disease (SCD) is a group of blood disorders typically inherited from a person's parents. The most common type is known as sickle cell anaemia. It results in an abnormality in the oxygen-carrying protein haemoglobin found in red bl ...
.
Gardos channel blockers may work in the treatment of sickle cell anemia by blocking the efflux of potassium and water from red blood cells, thereby preventing the dehydration of red blood cells and stopping the polymerization of HbS.
The Gardos channel has been identified as
KCNN4
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4, also known as KCNN4, is a human gene encoding the KCa3.1 protein.
Function
The KCa3.1 protein is part of a potentially heterotetrameric voltage-independ ...
.
The "ICA" is for
Icagen, which is developing the drug.
References
Fluoroarenes
Acetamides
{{blood-drug-stub